The earnings report of Alembic Pharma for the first quarter has revealed a mixed performance. The company's gross margins are expected to surpass the impressive 75% mark. The report, authored by Shaunak Amin, provides a comprehensive analysis of the financial results. This description highlights the key points of the title, including the mixed earnings in Q1 and the potential expansion of gross margins beyond 75%. Watch Shaunak Amin, Managing Director, Alembic Pharmaceuticals, on ET Now.
#etnow #sharemarket #businessnews #englishnews #alembicpharma #q1 #q1earnings #q1update #q1results #grossmargins
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► [ Ссылка ]
Subscribe Now To Our Network Channels :-
Times Now : [ Ссылка ]
The NewsHour Debate : [ Ссылка ]
To Stay Updated Download the Times Now App :-
Android Google Play : [ Ссылка ]
Apple App Store : [ Ссылка ]
Social Media Links :-
Twitter - [ Ссылка ]
Facebook - [ Ссылка ]
G+ - [ Ссылка ]
Website - www.etnownews.com
